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Abstract 
Background:  Data on the success rate of sitafloxacin treatment in acute complicated urinary tract infection and 
pyelonephritis are limited.
Objectives: To determine the success rate of a new oral fluoroquinolone, sitafloxacin, in acute complicated urinary 
tract infection and pyelonephritis.
Methods: A prospective study of 30 patients who were diagnosed with acute complicated urinary tract infection 
and pyelonephritis was conducted. Oral sitafloxacin 50 mg twice a day was given for 7 days. All patients were fol-
lowed up at baseline, day 7, and day 14.
Results: The patient sample included 67 % females; the mean ± SD age was 49 ± 13 years. Twenty-one (70 %) 
patients had acute pyelonephritis and 9 (30 %) had complicated urinary tract infections. Twenty-two patients were 
positive for uropathogens. The most frequently isolated pathogen was E. coli 11 non-extended spectrum beta-lacta-
mase (ESBL) producing and 5 ESBL-producing strains. Of the 22 isolated uropathogens, 19 (86 %) isolates were sensi-
tive to sitafloxacin. At day 14, 29 of 30 (97 %) were clinically cured and 21 of 22 (95 %) were microbiologically cured. 
No patients discontinued sitafloxacin due to adverse events.
Conclusions: These results support the use of oral sitafloxacin in complicated urinary tract infections and acute 
pyelonephritis. However, further larger studies are required to confirm these results.
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Impacts of findings on practice statements
  • Oral sitafloxacin demonstrated high rates of micro-
biological success in the treatment of acute compli-
cated UTI and pyelonephritis.
  • Oral sitafloxacin demonstrated high rates of clinical 
success in the treatment of acute complicated UTI 
and pyelonephritis.
  • Overall tolerability profile of sitafloxacin is favorable.
Background
Complicated urinary tract infections and acute pyelone-
phritis are relatively common infectious genitourinary 
problems. A complicated urinary tract infection localizes 
to the lower or upper urinary tract and is related to struc-
tural or functional abnormalities that may increase the 
risk of treatment failure, urinary tract obstruction and 
urinary bladder dysfunction (Grabe et  al. 2013). Acute 
pyelonephritis is commonly described as an infection 
of the upper urinary tract that includes fever and flank 
pain. It is an exudative purulent localized inflammation 
of the renal pelvis and kidney (Grabe et al. 2013). These 
are potentially serious infections that require prompt 
and effective antibiotic therapy. Renally excreted fluoro-
quinolones, such as levofloxacin and ciprofloxacin, are 
frequently prescribed for treatment (Hooton 2003). For 
patients who can tolerate oral therapy, empiric treatment 
with an oral fluoroquinolone is an optimal treatment. 
Fluoroquinolones used to previously treat urinary tract 
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infections include ciprofloxacin, levofloxacin, norfloxacin 
and ofloxacin (Gupta et al. 2011; Singh et al. 2013). A pre-
vious study of 28 hospitals in Thailand showed that 44 % 
of Escherichia coli isolated from the urine was resistant 
to ciprofloxacin and found a correlation between the 
incidence of ciprofloxacin-resistant E. coli bacteremia 
and the upward trend in quinolone use in the commu-
nity (Polwichai et al. 2009). In 2008, sitafloxacin, a potent 
broad-spectrum oral fluoroquinolone, was launched 
(Keating 2011). This drug is mainly renally excreted as 
an unchanged drug (Payne et  al. 2005; O’Grady et  al. 
2001). Sitafloxacin possesses activity against a variety of 
uropathogens, including E. coli (Keating 2011). Based 
on susceptibility rates, the activity of sitafloxacin against 
E. coli appeared greater than that of levofloxacin or cip-
rofloxacin. The bioavailability of sitafloxacin is 100  %, 
and food intake does not affect the pharmacokinetics of 
this drug to a significant extent (Nakashima et al. 1995). 
Approximately 80  % of sitafloxacin was excreted in the 
urine within 72 h of administration (Keating 2011). Oral 
sitafloxacin 50  mg twice daily was considered an effec-
tive dosage in patients with complicated urinary tract 
infections (Keating 2011). For the patients suspected 
of having a poor response to the usual dose, the dosage 
may be increased to 100 mg twice daily and extended to 
a 14-day period. To date, data regarding the success rate 
of sitafloxacin in acute complicated urinary tract infec-
tion and pyelonephritis are relatively limited. In addition, 
the causative uropathogens may vary in each geographic 
area. Thus, the objective of this study was to examine 
the treatment’s success rate in Thai patients diagnosed 
with acute complicated urinary tract infection and 
pyelonephritis.
Methods
The present study was designed as a pilot prospec-
tive single-arm study involving 30 patients at the Bam-
rasnaradura Infectious Diseases Institute, Ministry of 
Public Health, Nonthaburi, Thailand. This trial was 
performed in compliance with the Declaration of Hel-
sinki and approved by the institutional review boards. 
Written informed consent was obtained from every 
patient before the initiation of the study procedures. 
The period of enrolment was from November 2013 to 
October 2014. The primary objective was to study the 
rate of microbiological eradication in patients at day 14. 
The secondary objectives were to study microbiologi-
cal eradication at day 7, clinical success at day 14, and 
the tolerability to sitafloxacin. Inclusion criteria were 
as follows: (1) patients who were 18–70 years of age, (2) 
those with complicated urinary tract infections or acute 
pyelonephritis, and (3) those who participated and pro-
vided informed consent. A complicated urinary tract 
infection was defined as a urinary infection occurring in 
a patient with a structural or functional abnormality of 
the genitourinary tract, urinary tract stone, urinary tract 
obstruction, neurogenic bladder, or indwelling urethral 
catheter, for example. Exclusion criteria were as follows: 
(1) patients who could not tolerate oral therapy, (2) those 
having significant immune deficiency, such as receiving 
chemotherapy or having human immune deficiency virus 
infection, (3) having septic shock or unstable vital signs, 
(4) having prostatitis, perinephric abscess, or intra-renal 
abscess, (5) history of allergy to fluoroquinolones, (6) 
underlying diabetes mellitus, (7) history of epilepsy, and 
(8) myasthenia gravis. Prostatitis was excluded by a his-
torical and physical examination, including digital rectal 
examination and ultrasonography. One dose of systemic 
intravenous antibiotic treatment was allowed within 24 h 
prior to enrolment, including a third-generation cephalo-
sporin or aminoglycoside.
All eligible patients received oral sitafloxacin 50  mg 
twice a day for 7  days. The treatment period was 
extended up to 14  days, depending on the treatment 
response, including the delayed resolution of fever and/
or symptoms for more than 5  days. The dosage was 
increased from 50 mg twice a day to 100 mg twice a day 
in cases of clinical improvement, despite the sensitivity 
indicating sitafloxacin resistance. The patients had fol-
low-up visits at day 7 and day 14 after initiation of sita-
floxacin, at which time they were assessed clinically and 
blood samples were taken. Patients provided midstream 
urine samples for examination; these were sent for cul-
ture before the first dose of study medication and sub-
sequent visits. Urine samples were obtained by straight 
catheterization if urine catheters were placed. Levels 
of >105  CFU/mL uropathogens in midstream urine in 
women, >104  CFU/mL in midstream urine in men, or 
in straight catheter urine in women, were considered 
to be significant uropathogens in complicated urinary 
tract infections. A level of >104  CFU/mL uropathogens 
in midstream urine was considered to be significant in 
acute uncomplicated pyelonephritis in women. In  vitro 
susceptibility tests of sitafloxacin were performed by 
the disk diffusion method. Escherichia coli ATCC25922, 
Pseudomonas aeruginosa ATCC 27853, and Enterococcus 
faecalis ATCC29212 were used as reference strains. Inhi-
bition zone diameters ≥19  mm and ≤15  mm were the 
breakpoints for susceptibility for sensitive and resistant 
gram-negative uropathogens and gram-positive uropath-
ogens isolated from urine. An inhibition zone diameter 
>15 to <19 mm was an intermediate breakpoint for these 
uropathogens.
Laboratory parameters, including complete blood cell 
count, kidney enzymes, erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP), and liver enzymes were 
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assessed at the baseline visit and on day 7. The dosage 
of sitafloxacin was 50 mg per day for patients with esti-
mated glomerular filtration rate (eGFR) ≥30 to <50 mL/
min/1.73  m2 and 50  mg every other day for patients 
with eGFR 10  to <30  mL/min/1.73  m2. The eGFR was 
calculated by the Modification in Diet in Renal Disease 
(MDRD). The eGFR MDRD was calculated as the fol-
lowing: 186× serum creatinine−1.154 × age−0.203 × (0.742 
if female). Subjects whose initial uropathogens were 
resistant to sitafloxacin could remain in the study if they 
improved clinically; in this case, they were included in 
the analysis. In such cases, the dosage of sitafloxacin was 
adjusted to 100 mg twice daily. Clinical cure was assessed 
by the investigator and defined as resolution of initial 
clinical signs and symptoms without antibiotic treat-
ment. Microbiological response was assessed accord-
ing to results of the urine culture at follow-up visits. 
“Microbiological cure” was assigned to patients whose 
urine culture demonstrated elimination of their study 
entry uropathogens. At day 14, patients were assigned a 
response of “presumed microbiological cure” if a urine 
culture was not available at day 14 but a microbiological 
cure at day 7 combined with a clinical cure at day 14 was 
documented. Adverse events included events reported by 
patients and those observed as laboratory abnormalities.
The analyses were performed using the intention-to-
treat principle. Frequencies and the mean  ±  SD were 
used to describe clinical variables and laboratory vari-
ables. The paired t test was used to compare means of 
variables between the baseline visit and day 7. A P value 
<0.05 was considered statistically significant. All analyses 
were performed using SPSS version 15.0 (SPSS Inc., Chi-
cago, IL, USA).
Results
Table 1 shows the baseline characteristics of 30 patients. 
Of the total, 67 % were female; the mean ± SD age was 
49 ± 13 years. Sixty percent of patients were treated with 
outpatient antibiotic therapy and 40 % received inpatient 
therapy. Twenty-one (70 %) patients had acute pyelone-
phritis, and 9 (30 %) had complicated urinary tract infec-
tions. Twenty-two patients had positive uropathogens. 
The most frequently isolated pathogens included 11 non-
extended spectrum beta-lactamase (ESBL)-producing E. 
coli and 5 ESBL-producing E. coli. Of 22 isolated uropath-
ogens, 19 (86  %) isolates were sensitive to sitafloxacin. 
Two sitafloxacin-resistant isolates included Enterobacter 
cloacae and Klebsiella pneumoniae and one sitafloxacin-
intermediate isolate was methicillin-resistant Staphylo-
coccus aureus (MRSA). Among 16 isolates with E. coli, 
including 11 non- ESBL producing strains and 5 ESBL-
producing strains, all were sensitive to sitafloxacin. All 5 
ESBL-producing strains were resistant to ciprofloxacin, 
norfloxacin, cefotaxime, ceftazidime, and cefepime. Of 7 
strains resisted to norfloxacin and ciprofloxacin, 5 strains 
were sensitive to sitafloxacin 2 strains resisted to sitaflox-
acin, including E. cloacae and K. pneumoniae.
In terms of treatment response at day 7, among the 22 
positive urine cultures at baseline visits, 21 (95  %) were 
microbiologically cured. Two of 21 patients were presumed 




 Male 10 (33 %)
 Female 20 (67 %)
Age, years, mean ± SD 49 ± 13
Body weight, kg, mean ± SD 62 ± 12
Laboratory parameters
Hematocrit, mg %, mean ± SD 37 ± 6
White blood cells count, cells/mm3, mean ± SD 11,340 ± 5,496
Platelet, cells/mm3, mean ± SD 305,433 ± 115,971
Neutrophil, %, mean ± SD 75 ± 14
ESR, millimeters per hour, mean ± SD 46 ± 29
C-reactive protein, mg/L, mean ± SD 35 ± 31
BUN, mg/dl, mean ± SD 15 ± 11
Creatinine, mg/dl, mean ± SD 1.13 ± 0.76
Aspatate aminotransferase, U/L, mean ± SD 33 ± 34
Alanine aminotransferase, U/L, mean ± SD 37 ± 45
Total bilirubin, mg/dl, mean ± SD 1.4 ± 3.9
Albumin, mg/dl, mean ± SD 4.0 ± 0.5
Urinary tract infection (UTI) diagnosis
 Acute pyelonephritis 21 (70 %)
 Complicated UTI 9 (30 %)
  Stroke with neurogenic bladder 3
  Catheter-related UTI 2
  Ureteric stone with hydronephrosis 2
  UTI in men 2
Positive urine culture 22 (73 %)
 E. coli 11
 ESBL producing E. coli 4
 ESBL producing E. coli + ESBL producing K. pneu-
moniae
1
 Enterobacter cloacae 1
 Enterococcus fecalis 1
 Klebseilla pneumoniae 1
 Morganella morganii 1
 MRSA 1
 Coagulase negative Staphylococcus 1
Sensitivity to sitafloxacin, n = 22
 Sensitive 19 (86 %)
 Intermediate 1 (5 %)
 Resistant 2 (9 %)
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to have a microbiological cure. The mean ± SD white blood 
cell count in the complete blood count was 7710 ±  3452 
cell/mm3 and the mean  ±  SD percentage of neutrophils 
was 58 ± 11 %. The ESR was 50 ± 30 mm per hour. The 
C-reactive protein was 13 ± 18 mg/L. By repeated meas-
urement analysis, there was a significant decline in C-reac-
tive protein from the baseline visit (P < 0.001) but not in 
ESR (P = 0.505). At day 14, 29 of 30 (97 %) patients were 
clinically cured and 21 of 22 (95 %) patients were microbio-
logical cured as shown in Fig. 1. One female patient with 
clinical failure was diagnosed to have acute pyelonephritis 
with ESBL-producing E. coli. This isolate was resistant to 
ciprofloxacin and norfloxacin but not sitafloxacin. Her clin-
ical symptoms worsened after 5 days of treatment, so sita-
floxacin was switched to intravenous ertapenem. In terms 
of tolerability, none of the patients discontinued sitafloxa-
cin due to adverse events. At day 7, the mean ± SD aspar-
tate aminotransferase was 22 ± 7 U/L and the mean ± SD 
alanine aminotransferase was 30  ±  17  U/L. By repeated 
measurement analysis, there were no differences in aspar-
tate aminotransferase (P = 0.105) and alanine aminotrans-
ferase (P = 0.390) between the baseline visit and day 7. No 
initially isolated uropathogens developed resistance to sita-
floxacin during treatment.
Discussion
In the treatment of complicated urinary tract infections 
and acute pyelonephritis, determining the underlying 
disease and prompt and effective antibiotic treatment are 
essential. E. coli was the most commonly isolated patho-
gen and few gram-positive uropathogens were isolated in 
the present study. Of note, one-third of them were ESBL-
producing strains. In addition, a previous report in Thais 
demonstrated that the incidence of ESBL-producing E. 
coli septicemia was 9.9 cases per 10,000 hospital admis-
sions. The risk factors associated with ESBL-producing 
E. coli septicemia were hospital acquisition, previous 
use of a fluoroquinolone, and the use of a central venous 
catheter (Anunnatsiri et al. 2012). Our findings highlight 
a concern that there was a high rate of drug-resistant 
uropathogens among the causative uropathogens and 
a broad range of uropathogens in this setting. This may 
be partly explained by the fact that this study involved 
patients with complicated urinary tract infections. In 
general, drug-resistant uropathogens are more com-
monly isolated, and the causative uropathogens vary 
widely when compared to isolates from patients with 
uncomplicated urinary tract infections. Nonetheless, 
almost all patients’ infections were microbiologically 
eradicated.
Sitafloxacin demonstrated high rates of microbiologi-
cal and clinical success in this study, i.e., >90 %. Kawada 
and colleagues demonstrated that >90  % clinical effi-
cacy was achieved with sitafloxacin 50  mg twice daily 
for 7 days (Kawada et al. 2008a). In addition, a previous 
study demonstrated that >80 % of isolates from patients 
with complicated urinary tract infections remained sus-
ceptible to sitafloxacin, while the rates for levofloxacin 
and third-generation cephalosporins were lower (Kawada 
et al. 2008b). Fluoroquinolone resistance in E. coli mainly 
develops by mutations of DNA gyrase and topoisomerase 
IV (Hoshino et al. 1994). The recommended sitafloxacin 
dosage for treatment of acute pyelonephritis and com-
plicated urinary tract infections was 50–100  mg twice 
daily for 7–14 days. The inhibitory activity of sitafloxacin 
against such enzymes was greater than that of fluoro-
quinolones (Okumura et  al. 2008; Onodera et  al. 1999). 
The MIC90 of sitafloxacin, levofloxacin, ciprofloxacin, 
and moxifloxacin against E. coli clinical isolates were 
1–2, 16, 16–32, and 16–32 μg/mL, respectively (Keating 
2011). For fluoroquinolone, the maximum concentration 
(Cmax): minimum inhibitory concentration (MIC) ratio 
and area under the curve (AUC):MIC ratio are appropri-
ate parameters to predict activity and likelihood of devel-
oping drug resistance (Keating 2011). A previous study 
demonstrated that sitafloxacin 50  mg oral twice daily 
achieving the Cmax:MIC ratio >5 were associated with 
eradication rate of 96  % in respiratory tract pathogen. 
(Kohno et al. 2013) The dosage of sitafloxacin 100 mg oral 
twice daily achieved a higher Cmax. In addition, muta-
tion prevention concentration (MPC) of sitafloxacin had 
a lower concentration level than other quinolones. This 
suggests that sitafloxacin has a higher barrier to develop-
ing resistance and the majority of levofloxacin-resistant 
E. coli remains susceptible to sitafloxacin. Two sitaflox-
acin-resistant isolates were found in the present study 
without treatment failure. In addition, a double dose of 
sitafloxacin was allowed to treat these patients to over-
come this effect. Previous studies showed that sitafloxa-
cin was more active than levofloxacin, ciprofloxacin and Fig. 1 Treatment outcomes at day 14 after sitafloxacin therapy
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moxifloxacin against bacteria isolated from Thai and Jap-
anese patients including ESBL-producing gram-negative 
strains (Tiengrim et  al. 2012; Amano et  al. 2013; Naka-
mura et  al. 2014; Matsumoto et  al. 2012). Nevertheless, 
drug-resistance is one of the major challenges in treating 
these urinary tract infections due to an increased inci-
dence of fluoroquinolone-resistant uropathogens (Czaja 
et al. 2007).
The most frequently reported adverse reactions of sita-
floxacin included diarrhea and transaminitis (Matsumoto 
et al. 2012). Diarrhea symptoms were usually mild, as in 
previous reports (Hooton 2003; Matsumoto et al. 2012). 
None of the patients discontinued sitafloxacin due to 
adverse events. Likewise, no elevation of aspartate ami-
notransferase or alanine aminotransferase was found 
(P  >  0.05). Therefore, the overall tolerability profile of 
sitafloxacin is favorable. A limitation of the present study 
is that the sample size was relatively small and there were 
no comparators. Additional larger studies and longer 
follow-up periods are needed to confirm our findings. In 
addition, the minimum inhibitory concentration (MIC) 
of sitafloxacin was not addressed. However, the correla-
tion of the inhibition zone diameter of sitafloxacin as 
determined by the disk diffusion method and the MIC 
determined by the agar dilution method has been dem-
onstrated (Thamlikitkul and Tiengrim 2014).
Oral sitafloxacin 50–100  mg twice daily administered 
for 7–14  days was effective in the treatment of compli-
cated urinary tract infections and acute pyelonephritis. 
All patients tolerated sitafloxacin well. This result sup-
ports the use of oral sitafloxacin against such infections. 
However, further larger studies are required to confirm 
these results.
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